A Network Meta-Analysis of First-Line Systemic Therapies for Advanced Hepatocellular Carcinoma

Barinder Singh¹, Akanksha Sharma², Pankaj Rai², Shubhram Pandey² ¹Pharmacoevidence, London, UK, ²Pharmacoevidence, SAS Nagar, Mohali, PB, India

Conclusion

indicate the availability of more first-line options in the near future for advanced HCC patients

Background

- Hepatocellular carcinoma (HCC) is a primary tumor of the liver and constitutes more than 90% of the liver tumor
- More than 50% of patients with HCC are diagnosed at later stage of disease; the systemic therapy is usually the recommended treatment option for such patients
- Over the past few years, number of approved first-line systemic therapies for HCC patients has expanded greatly, and numerous drugs and their combinations have been evaluated in this setting


Objective

• This research aimed to compare the first-line systemic therapies for locally advanced and metastatic unresectable HCC

Methodology


- The review followed the standard methodology for conducting SLRs as per the guidelines provided by the National Institute for Health and Care Excellence (NICE) and Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)
- Key biomedical databases (Embase, MEDLINE, and Cochrane Central Trials Register) were searched for randomized controlled trials (RCTs) published from database inception to December 2022 to identify relevant evidence (Figure 1)
- Two independent reviewers performed the screening and data extraction activities with conflicts resolved by a third independent reviewer
- Network meta-analysis (NMA) used generalized linear models with random effects within a Bayesian framework (using informative priors)

Figure 1: PICOS eligibility criteria for selection of evidence



Presented at ISPOR • Boston, USA, May 7-10, 2023

Atezolizumab plus bevacizumab was confirmed to be an effective first-line treatment to improve survival in patients with advanced HCC. The promising results of immunotherapy combinations with TKIs and other agents







For further queries, please contact Barinder.Singh@Pharmacoevidence.com



Sponsorship



Evidence

